Reproductive Sciences

, Volume 19, Issue 4, pp 383–390 | Cite as

Relationship Between Anti-Müllerian Hormone (AMH) and Insulin Levels During Different Tanner Stages in Daughters of Women With Polycystic Ovary Syndrome

  • Teresa Sir-PetermannEmail author
  • Amanda Ladrón de Guevara
  • Ethel Codner
  • Jessica Preisler
  • Nicolás Crisosto
  • Bárbara Echiburú
  • Manuel Maliqueo
  • Fernando Sánchez
  • Francisco Perez-Bravo
  • Fernando Cassorla



We have previously described increased serum levels of anti-Müllerian hormone (AMH) and stimulated insulin in daughters of women with polycystic ovary syndrome(PCOS), suggesting that these girls may have an altered ovarian follicular development which may be modulated by insulin. However, the specific relationship between serum AMH and insulin levels during each Tanner stage of puberty in this cohort has not been established.


The aim of our study was to establish the relationship between AMH and poststimulated insulin serum concentrations during each stage of puberty in daughters of women with PCOS (PCOSd), compared to daughters of control women (Cd).


We studied 135 PCOSd and 93 Cd classified according to their Tanner stage. Gonadotrophins, sex steroids, sex hormone-binding globulin (SHBG), and AMH were determined in a fasting sample. Ovarian volume was measured by pelvic ultrasound. In addition, in both groups we performed an oral glucose tolerance test with measurements of glucose and insulin.


Anti-Müllerian hormone levels were significantly higher in PCOSd compared to Cd at all Tanner stages. Daughters of women with PCOS having AMH concentrations greater than 2 standard deviation (SD) above the mean AMH value for the Cd group showed decreased serum follicle-stimulating hormone (FSH) concentrations and increased stimulated levels of insulin during Tanner stages I, II, and III.


Anti-Müllerian hormone levels are increased in PCOSd during all stages of puberty. We suggest that those PCOSd with the highest AMH levels probably represent a group of girls with more severe ovarian dysfunction and metabolic derangements.


hyperandrogenism puberty anti-Müllerian hormone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Franks S. Polycystic ovary syndrome. N Engl J Med. 1995; 333: 853–861.CrossRefGoogle Scholar
  2. 2.
    Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009;24(7):1548–1555.CrossRefGoogle Scholar
  3. 3.
    Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?. J Clin Endocrinol Metab. 2006;91(1):22–24.CrossRefGoogle Scholar
  4. 4.
    Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–1021.CrossRefGoogle Scholar
  5. 5.
    Cate RL, Mattaliano RJ, Heisson C, Tizard R, Farber NM, Cheung A. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45(5):685–698.CrossRefGoogle Scholar
  6. 6.
    Josso N, di Clemente N. TGF-beta Family Members and Gonadal Development. Trends Endocrinol Metab. 1999;10(6):216–222.CrossRefGoogle Scholar
  7. 7.
    Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, Cleemann L, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–5010.CrossRefGoogle Scholar
  8. 8.
    Sir-Petermann T, Codner E, Maliqueo M, Echiburu B, Hitschfeld C, Crisosto N, et al. Increased anti-Mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(8):3105–3109.CrossRefGoogle Scholar
  9. 9.
    Crisosto N, Codner E, Maliqueo M, Echiburú B, Sánchez F, Cassorla F, et al. Anti-mullerian hormone levels in peri-pubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(7):2739–2743.CrossRefGoogle Scholar
  10. 10.
    Sir-Petermann T, Codner E, Pérez V, Echiburú B, Maliqueo M, Ladrón de Guevara A, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(6):1923–1930.CrossRefGoogle Scholar
  11. 11.
    Zawadzky JK, Dunaif A. Diagnosis criteria: towards a rational approach. In: Hershmann JM, ed. Current issues in endocrinology and metabolism. Boston, MA: Blackwell. 1992;377–384.Google Scholar
  12. 12.
    Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355–359.CrossRefGoogle Scholar
  13. 13.
    Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109(1):45–46.CrossRefGoogle Scholar
  14. 14.
    Youlton R, Valenzuela C. Growth patterns in height and weight in children aged 0 to 17 years and cranial circumference in children aged 0 to 2 years from medium-high and high socioeconomic status in Santiago. Comparison with growth in children from medium-low and low status in the Northern area of Santiago. Rev Chil Pediatr 1990;Spec. No:1–22.Google Scholar
  15. 15.
    Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140(7):815–830.CrossRefGoogle Scholar
  16. 16.
    Tellez R, Frenkel J. Clinical evaluation of body hair in healthy women. Rev Med Chile. 1995;123(11):1349–1354.PubMedGoogle Scholar
  17. 17.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care Suppl. 2004;1:S5-S1.Google Scholar
  18. 18.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.CrossRefGoogle Scholar
  19. 19.
    Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–1470.CrossRefGoogle Scholar
  20. 20.
    Swanson M, Sauerbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound. 1981;9(5):219–222.CrossRefGoogle Scholar
  21. 21.
    Rey RA, Codner E, Iniguez G, Bedecarras P, Trigo R, Okuma C, et al. Low risk of impaired testicular Sertoli and Leydig cell functions in boys with isolated hypospadias. J Clin Endocrinol Metab. 2005;90(11):6035–6040.CrossRefGoogle Scholar
  22. 22.
    Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118–1121.CrossRefGoogle Scholar
  23. 23.
    Sampaolo P, Livieri C, Montanari L, Paganelli A, Salesi A, Lorini R. Precocious signs of polycystic ovaries in obese girls. Ultrasound Obstet Gynecol. 1994;4(4):310–315.CrossRefGoogle Scholar
  24. 24.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.PubMedGoogle Scholar
  25. 25.
    Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulose cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81(1):302–309.PubMedGoogle Scholar
  26. 26.
    Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A, et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(2):644–648.CrossRefGoogle Scholar
  27. 27.
    Sir-Petermann T, Echiburú B, Pérez V, Ladrón de Guevara A, Preisler J, Merino S, et al. Ovarian Function during Early Infancy in Daughters of Women with Polycystic Ovary Syndrome Treated with Metforming during Pregnancy. 91th Annual Meeting of Endocrine Society. 2009;P1-298.Google Scholar
  28. 28.
    Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 1988; 123(2):733–739.CrossRefGoogle Scholar
  29. 29.
    Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjö T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993;59(2):323–331.CrossRefGoogle Scholar
  30. 30.
    Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83(6):2001–2005.PubMedGoogle Scholar
  31. 31.
    Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to Gonadotrophin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994;79(6): 1686–1692.PubMedGoogle Scholar
  32. 32.
    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A. 17-hydroxyprogesterone responses to Gonadotrophin-releasing hormone disclose distinct phenotypes of functional ovarian hyper-androgenism and polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(11):4208–4217.CrossRefGoogle Scholar
  33. 33.
    Sir-Petermann T, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. Hum Reprod. 1993;8(11):1807–1812.CrossRefGoogle Scholar
  34. 34.
    Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 2010;1364:186–97.CrossRefGoogle Scholar
  35. 35.
    Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296(2):E238–E243.CrossRefGoogle Scholar
  36. 36.
    Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(3):787–96.CrossRefGoogle Scholar

Copyright information

© Society for Reproductive Investigation 2012

Authors and Affiliations

  • Teresa Sir-Petermann
    • 1
    Email author
  • Amanda Ladrón de Guevara
    • 1
  • Ethel Codner
    • 2
  • Jessica Preisler
    • 1
  • Nicolás Crisosto
    • 1
  • Bárbara Echiburú
    • 1
  • Manuel Maliqueo
    • 1
  • Fernando Sánchez
    • 1
  • Francisco Perez-Bravo
    • 3
  • Fernando Cassorla
    • 2
  1. 1.Endocrinology and Metabolism Laboratory, West Division, School of MedicineUniversity of ChileSantiagoChile
  2. 2.Institute of Maternal and Child Research (IDIMI)School of Medicine University of ChileSantiagoChile
  3. 3.Laboratory of Nutritional Genomics, Department of Nutrition, Faculty of MedicineUniversity of ChileSantiagoChile

Personalised recommendations